The market for In-Vitro Fertilization Market is expected to reach US$ 36,854.0 Mn in 2026.
The in-vitro fertilization market is expected to grow from $15,604.7 million in 2017 to $36,854.0 million in 2026, with a compounded annual growth rate of 10.1% projected from 2018 to 2026. A significant increase in couples having children later in life, as a result of increased preference for professional careers and technological advancements in IVF treatment, will drive market growth in the coming years.
Culture media currently have the largest market share among in vitro fertilization instruments. Increased research activities in improving culture media and the ability to preserve sperm without losing quality are major contributing factors. Increasing demand for egg processing media and the establishment of numerous egg cryobanks further bolster the market's growth for culture media. Strict regulatory mandates and the need to maintain optimum sterile conditions will propel the market growth of disposable devices at a faster rate.
Fresh non-donor is currently reigning in the type segment for the in-vitro fertilization market. The high success rate on the first try is the primary reason for its impressive market growth. Frozen non-donor will showcase outstanding growth in the next few years on account of an excellent live birth rate, better implementation, reduced cases of ectopic pregnancy, and a lower miscarriage rate.
Fertility clinics are dominating the end-user segment of the in-vitro fertilization market. The fertility clinic market is growing due to an increase in the number of couples opting for ART treatments such as intracytoplasmic sperm injection (ICSI) and gamete intrafallopian transfer (GIFT). Hospitals are showcasing steady growth on account of enhanced government funding to provide IVF treatment to poor families and rising public health awareness pertaining to infertility treatment.
North America is responsible for 35% of market growth and is the leading regional segment for the in-vitro fertilization market. The rising prevalence of infertility is one of the contributing factors to its market dominance. As per the research findings of the American Society for Reproductive Medicine (ASRM), approximately 6.7 million women are suffering from infertility in the United States, which represents 11.0% of the reproductive population. Europe has a 30% market share due to government initiatives that provide financial incentives for gametes freezing and IVF cycles. Asia Pacific represents 20% market share and will capture the market in the next few years on account of the presence of a large target population, the adoption of sophisticated technology, and low treatment costs in comparison to developed countries.
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Biopharmaceuticals specializing in the in-vitro fertilization market are Boston IVF, Cook Medical, Inc., Cooper Surgical, Inc., EMD Serono, Inc., Genea Biomedx, Irvine Scientific, Inc., OvaScience, Inc., Progyny, Inc., Thermo Fisher Scientific, Inc., and Vitrolife AB.
The market for In-Vitro Fertilization Market is expected to reach US$ 36,854.0 Mn in 2026.
The In-Vitro Fertilization Market is expected to see significant CAGR growth over the coming years, at 10.1%.
The report is forecasted from 2018-2026.
The base year of this report is 2017.
Cooper Surgical, Inc., EMD Serono, Inc., Genea Biomedx, Irvine Scientific, Inc., OvaScience, Inc., Progyny, Inc., Thermo Fisher Scientific, Inc are some of the major players in the global market.